Novavax (NVAX) Total Liabilities (2010 - 2026)

Novavax's Total Liabilities history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Total Liabilities fell 13.2% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (down 13.2% YoY), while the FY2025 annual figure was $1.3 billion, down 40.29% from the prior year.
• Total Liabilities was $1.2 billion for Q1 2026 at Novavax, down from $1.3 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $3.0 billion in Q2 2022 to a low of $1.2 billion in Q1 2026.
• Historically, Total Liabilities has averaged $2.2 billion across 5 years, with a median of $2.3 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 76.49% in 2022, then tumbled 42.28% in 2025.
• A 5-year view of Total Liabilities shows it stood at $2.9 billion in 2022, then fell by 13.08% to $2.5 billion in 2023, then dropped by 13.13% to $2.2 billion in 2024, then sank by 40.29% to $1.3 billion in 2025, then fell by 8.92% to $1.2 billion in 2026.
• The last three Total Liabilities figures came in at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.